The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Open accessAbstract
BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer. METHODS: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy. RESULTS: F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationColorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citationClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Silva e Sousa, A. H., Campos, F. G., Kiss, D. R., & Gama-Rodrigues, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141194.27992.32 · Cited by 1,893
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer
Maas, M., Beets-Tan, R. G. H., Lambregts, D. M. J., Lammering, G., Nelemans, P. J., Engelen, S. M. E., van Dam, R. M., Jansen, R. L. H., Sosef, M., Leijtens, J. W. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7176 · Cited by 1,117
Peeters, K. C. M. J., van de Velde, C. J. H., Leer, J. W. H., Martijn, H., Junggeburt, J. M. C., Kranenbarg, E. K., Steup, W. H., Wiggers, T., Rutten, H. J., & Marijnen, C. A. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.779 · Cited by 943
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Self-citationSmith, J. J., Strombom, P., Chow, O. S., Roxburgh, C. S., Lynn, P., Eaton, A., Widmar, M., Ganesh, K., Yaeger, R., Cercek, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5896 · Cited by 588
Self-citationPrevalence of Male and Female Sexual Dysfunction Is High Following Surgery for Rectal Cancer
Hendren, S. K., O'Connor, B. I., Liu, M., Asano, T., Cohen, Z., Swallow, C. J., MacRae, H. M., Gryfe, R., & McLeod, R. S. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000171299.43954.ce · Cited by 578
Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer
Park, I. J., You, Y. N., Agarwal, A., Skibber, J. M., Rodriguez-Bigas, M. A., Eng, C., Feig, B. W., Das, P., Krishnan, S., Crane, C. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7901 · Cited by 485
Self-citationFernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8541 · Cited by 438
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Maas, M., Lambregts, D. M. J., Nelemans, P. J., Heijnen, L. A., Martens, M. H., Leijtens, J. W. A., Sosef, M., Hulsewé, K. W. E., Hoff, C., Breukink, S. O., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4687-9 · Cited by 393
on behalf of the Rectal Cancer Consortium, Smith, J. J., Chow, O. S., Gollub, M. J., Nash, G. M., Temple, L. K., Weiser, M. R., Guillem, J. G., Paty, P. B., Avila, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1632-z · Cited by 391
Self-citationChua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., Tait, D., Massey, A., Tebbutt, N. C., & Chau, I. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70381-x · Cited by 319
Hu, H., Kang, L., Zhang, J., Wu, Z., Wang, H., Huang, M., Lan, P., Wu, X., Wang, C., Cao, W., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00348-4 · Cited by 302
Self-citationMismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Cercek, A., Dos Santos Fernandes, G., Roxburgh, C. S., Ganesh, K., Ng, S., Sanchez-Vega, F., Yaeger, R., Segal, N. H., Reidy-Lagunes, D. L., Varghese, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3728 · Cited by 238
Self-citationHamada, T., Zhang, X., Mima, K., Bullman, S., Sukawa, Y., Nowak, J. A., Kosumi, K., Masugi, Y., Twombly, T. S., Cao, Y., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0174 · Cited by 232
Cercek, A., Goodman, K. A., Hajj, C., Weisberger, E., Segal, N. H., Reidy-Lagunes, D. L., Stadler, Z. K., Wu, A. J., Weiser, M. R., Paty, P. B., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0056 · Cited by 224
Self-citationReese, J. B., Finan, P. H., Haythornthwaite, J. A., Kadan, M., Regan, K. R., Herman, J. M., Efron, J., Diaz, L. A., & Azad, N. S. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1998-x · Cited by 83
Self-citationAlex, A. K., Siqueira, S., Coudry, R. A., Santos, J., Alves, M. F. S., Hoff, P. M., & Riechelmann, R. P. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.11.001 · Cited by 61
Alatise, O. I., Knapp, G., Sharma, A. S., Chatila, W. K., Arowolo, O. A., Olasehinde, O. O., Famurewa, O. C., Omisore, A. D., Komolafe, A. O., Olaofe, O. O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27106-w · Cited by 54
Self-citationChanzá, N. M., Soukane, L., Barthélémy, P., Carnot, A., Gil, T., Casert, V., Vanhaudenarde, V., Sautois, B. R., Staudacher, L., den Brande, J. V., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08990-3 · Cited by 22
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0051 · Cited by 827
Self-citationRegulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Therapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Metabolism, metabolites, and macrophages in cancer
Li, M., Yang, Y., Xiong, L., Jiang, P., Wang, J., & Li, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01478-6 · Cited by 507
Metadata
- Authors
- Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., Stadler, Z., Yaeger, R., Smith, J. J., Rousseau, B., Argiles, G., Patel, M., Desai, A., Saltz, L. B., Widmar, M., Iyer, K., Zhang, J., Gianino, N., Crane, C., Romesser, P. B., Pappou, E. P., Paty, P., Garcia-Aguilar, J., Gonen, M., Gollub, M., Weiser, M. R., Schalper, K. A., & Diaz, L. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-06-23
- Volume
- 386
- Issue
- 25
- Pages
- 2363-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281732693
- Cited by
- 1,625
- References
- 37
- FWCI
- 121.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.